Physician profile
Julio A Baco
NPI 1295818730
$267,705.98
in general payments reported to CMS, 2019-2025
8 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $8,999 · 2021: $14K · 2022: $67K · 2023: $37K · 2024: $52K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $136K · Travel and Lodging: $9,680 · Food and Beverage: $5,700 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,862.50 |
| Travel and Lodging | $9,679.69 |
| Food and Beverage | $5,699.53 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $193,717.64 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Janssen Pharmaceuticals, INC | $36,363.15 | 2019-2024 | Symtuza |
| Gilead Sciences, INC. | $16,065.10 | 2022-2025 | Biktarvy, Epclusa |
| Merck Sharp & Dohme LLC | $13,213.40 | 2019-2025 | Pifeltro, Capvaxive, Gardasil 9 |
| Janssen Products, Lp | $7,139.92 | 2019-2022 | |
| Theratechnologies INC. | $971.65 | 2019-2022 | |
| Abbvie INC. | $221.63 | 2024-2025 | |
| Glaxosmithkline, LLC. | $13.49 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Baco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.